Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.

A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC ... The VEGF TKI lenvatinib has also ...

Lenvatinib (Kisplyx), plus everolimus, is available on the NHS as a possible treatment for previously treated advanced renal cell carcinoma in adults only if they are still well enough to carry out ...

In this trial, they looked at a drug called lenvatinib. Lenvatinib is a targeted cancer drug. It works by blocking certain proteins that help cells to grow blood vessels. All cancer cells need blood ...

2.1 Pembrolizumab (Keytruda, MSD), in combination with lenvatinib (Kisplyx, Eisai), is indicated for 'the first-line treatment of advanced renal cell carcinoma in adults'. 2.3 The price of lenvatinib ...